Meridian Medical Inc. Breakthrough in Clinical Cardiology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 15, 2010) - Meridian Co., Ltd. (OTCBB: MRDAF), a company engaged in the research, development, manufacturing, and sales of advanced medical devices is proud to announce that through its Distribution Partner Meridian Medical Inc. (MMI) the publication of an article in the prestigious Townsend Letter, May 2010 issue.

The research article clearly validates the importance of the Meridian Digital Pulse Wave Analyzer in many high risk health care concerns, as published in the May edition of the Townsend Letter. The article entitled 'Breakthrough in Clinical Cardiology: In-Office Assessment with Pulse Wave Velocity (PWV) and Digital Pulse Analysis (DPA)' coauthored by Brian Scott Peskin, BSEE, with Robert Jay Rowen, MD.

This article goes on to say it 'explores an exciting, noninvasive, easy-to-use, and economical method of assessing patients' cardiovascular physiologic status that is backed by more than 25 years of advanced research in medical physics'.

The article also quotes the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) having added PWV measurement as an early index of large artery stiffening in their 2007 Guideline for the Management of Arterial Hypertension. The Digital Pulse Analysis (DPA) is the next evolution in pulse wave velocity (PWV), and is based on the measurement of reflected infrared light (IR).

Another very exciting highlight of the article is not only cardiovascular screenings but it shows strong promise in the areas of early detection Diabetes.

In the ongoing study-2010/2009 IOWA (Investigation Oils with Respect to Arterial Blockage) IOWA's goal is to assess the intervention of plant-based, bio identical PEOs and measure their effectiveness in both stopping progression of and reversing existing atherosclerosis; that is, reversing "hardening of the arteries" as evidenced not by hopeful but ineffective "surrogates", but by detailed DPA patient profiles, which are a much more direct measure of the physiologic CV state. The study ultimately will include over 200 participants.

"We are very fortunate to have two such prestigious and talented researchers involved with our important technology," says Lorenzo Lepore, MMI's Director of the DPA division. "We are excited to finally have all the benefits of the DPA recognized and validated. It's an honor for MMI to contribute in the fight against Cardio Vascular disease in this way."

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

For the full article check: http://www.lapexbcs.com/media/downloadables.php